- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 14/68 - Melanocyte-stimulating hormone [MSH]
Patent holdings for IPC class C07K 14/68
Total number of patents in this class: 87
10-year publication summary
6
|
7
|
8
|
7
|
5
|
5
|
1
|
2
|
5
|
3
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
The Arizona Board of Regents on Behalf of the University of Arizona | 2153 |
12 |
Novo Nordisk A/S | 2285 |
9 |
Palatin Technologies, Inc. | 73 |
8 |
Rhythm Pharmaceuticals, Inc. | 73 |
5 |
Board of Regents, The University of Texas System | 5782 |
4 |
H. Lee Moffitt Cancer Center and Research Institute, Inc. | 940 |
4 |
Intezyne Technologies, Inc. | 55 |
4 |
Ipsen Pharma S.A.S. | 375 |
4 |
Provincial Health Services Authority | 186 |
4 |
Stc.unm | 678 |
4 |
TXP Pharma GmbH | 11 |
4 |
Genzyme Corporation | 1243 |
3 |
The University of British Columbia | 1497 |
3 |
Trustees of Tufts College | 873 |
2 |
Tufts Medical Center, Inc. | 221 |
2 |
Endevica bio, Inc. | 13 |
2 |
The Trustees of the University of Pennsylvania | 4317 |
1 |
Aileron Therapeutics, Inc. | 80 |
1 |
Fondazione Irccs "ca' Granda - Ospedale Maggiore Policlinico" | 47 |
1 |
Nanyang Technological University | 1999 |
1 |
Other owners | 9 |